Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of cell background on pharmacological rescue of mutant CFTR.

American journal of physiology. Cell physiology - 1 Apr 2010

Pedemonte Nicoletta, Tomati Valeria, Sondo Elvira, Galietta Luis J V

Abstract excerpt

Cystic fibrosis (CF) is caused by mutations in the CFTR chloride channel. Deletion of phenylalanine 508 (F508del), the most frequent CF mutation, impairs the maturation and gating of the CFTR protein. Such defects may be corrected in vitro by pharmacological modulators named as correctors and potentiators, respectively. We have evaluated a panel of correctors and potentiators derived from various sources to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Molecular Structure

Share to Pharmaceutical Preparations

Share to Rats, Inbred F344

Source

Identifiers

PMID: 20053923
DOI: 10.1152/ajpcell.00404.2009

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of cell background on pharmacological rescue of mutant CFTR.PMID 20053923Read ↗

Corrector combination therapies for F508del-CFTR.Semantic proximity Read ↗

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulatorsSemantic proximity Read ↗

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.Semantic proximity Read ↗

Current development of CFTR potentiators in the last decade.Semantic proximity Read ↗

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Semantic proximity Read ↗

Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Semantic proximity Read ↗

Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells.Semantic proximity Read ↗

F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Semantic proximity Read ↗

Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.Semantic proximity Read ↗

Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background.Semantic proximity Read ↗

A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.Semantic proximity Read ↗

CFTR pharmacology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.